Clinical Trial · NCT04588064

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

Overview

To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

N/A

Contacts

Long Sun, PhD (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT04588064

Drug / Compound

FAPI

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: DOTA

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

(ii) who accepted undergoing paired 18F-FDG and 68Ga-FAPI-46 PET/CT, with completion within one week of each other;
(iii) with planned surgical resection within one month after PET/CT examinations;

Exclusion

(iv) with concurrent diagnosis of other malignant tumors;
(v) with poor image quality or lesions difficult to measure.
(i) without surgical treatment;
(ii) receiving antitumor treatment prior to surgery;
(iii) whose postoperative pathology revealed adenocarcinoma beyond stage IA or benign pulmonary lesions;